These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36446748)

  • 1. Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
    Launois A; De Raucourt E; Martin-Toutain I; Samdjee F; Le Dore S; Ferre E; Flaujac C
    Haemophilia; 2023 Jan; 29(1):374-376. PubMed ID: 36446748
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
    Brophy DF; Martin EJ; Kuhn J
    Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 6. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients on emicizumab prophylaxis with previously tolerized inhibitors: Is there a risk of inhibitors recurrence?
    Hassan E; Lancashire J; Motwani J
    Haemophilia; 2022 Mar; 28(2):e36-e38. PubMed ID: 34821004
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world data on emicizumab prophylaxis in the Milan cohort.
    Arcudi S; Gualtierotti R; Marino S; Nicolò G; Biguzzi E; Ciavarella A; Boscarino M; Siboni SM; Schiavone L; Novembrino C; Valsecchi C; Peyvandi F
    Haemophilia; 2022 Sep; 28(5):e141-e144. PubMed ID: 35853212
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot
    Nakajima Y; Takami E; Nakano H; Nogami K
    Haemophilia; 2022 Sep; 28(5):e149-e152. PubMed ID: 35947585
    [No Abstract]   [Full Text] [Related]  

  • 11. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.
    Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF
    Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.
    Doshi BS; Witmer CM
    Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659
    [No Abstract]   [Full Text] [Related]  

  • 15. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.
    Kershaw G; Dix C; Chen VM; Cai N; Khoo TL
    Pathology; 2022 Oct; 54(6):755-762. PubMed ID: 35577608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy.
    Capdevila L; Borgel D; Lasne D; Lacroix-Desmazes S; Desvages M; Delignat S; Bally C; Frenzel L; Harroche A
    Haemophilia; 2021 Jul; 27(4):e581-e584. PubMed ID: 34004050
    [No Abstract]   [Full Text] [Related]  

  • 17. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 18. Do we need all that emicizumab?
    Lehtinen AE; Lassila R
    Haemophilia; 2022 Mar; 28(2):e53-e55. PubMed ID: 34970820
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful in-patient management of COVID-19 infection in an old severe haemophilia A patient on emicizumab with multiple prothrombotic comorbidities.
    Houssiau H; Hermans C
    Haemophilia; 2023 Mar; 29(2):674-675. PubMed ID: 36639948
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.